Minerva Surgical, Inc. (UTRS)
- Previous Close
0.0010 - Open
0.0010 - Bid --
- Ask --
- Day's Range
0.0010 - 0.0010 - 52 Week Range
0.0010 - 14.0000 - Volume
10 - Avg. Volume
2,479 - Market Cap (intraday)
8,879 - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-7.6100 - Earnings Date Apr 29, 2024 - May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
minervasurgical.comRecent News: UTRS
Performance Overview: UTRS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UTRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UTRS
Valuation Measures
Market Cap
8.88k
Enterprise Value
32.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
0.00
Enterprise Value/Revenue
0.63
Enterprise Value/EBITDA
-1.60
Financial Highlights
Profitability and Income Statement
Profit Margin
-64.71%
Return on Assets (ttm)
-27.34%
Return on Equity (ttm)
-160.07%
Revenue (ttm)
51.69M
Net Income Avi to Common (ttm)
-33.45M
Diluted EPS (ttm)
-7.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
11.12M
Total Debt/Equity (mrq)
215.01%
Levered Free Cash Flow (ttm)
-18.49M